Stock analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK opened at $0.49 on Friday. The company has a market cap of $4.12 million, a P/E ratio of -0.21 and a beta of 0.38. The stock has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.87. Evoke Pharma has a 12 month low of $0.41 and a 12 month high of $2.40.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The company had revenue of $1.68 million for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- What is a buyback in stocks? A comprehensive guide for investors
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Does a Stock Split Mean?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Most active stocks: Dollar volume vs share volume
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
